Skip to content
Taiwan
-
GC Biopharma expands Asian footprint with Hunter Syndrome approvals in India, Taiwan
The company said India’s Central Drugs Standard Control Organisation (CDSCO) approved the intravenous (IV) formulation, while Taiwan’s Food and Drug Administration (TFDA) approved both Hunterase IV and Hunterase ICV.
-
Bora Group expands US biologics footprint with US$127.5M MacroGenics CDMO acquisition
The acquisition includes MacroGenics’ biologics drug substance manufacturing facility in Rockville, Maryland, as well as a warehousing center in Frederick, Maryland, located about 30 miles away.
-
BioDuro expands API production to Taiwan through new joint venture with Cenra
The venture aims to deliver comprehensive active pharmaceutical ingredient (API) services, covering everything from initial development stages through full-scale commercial production.